| 1 | Antituberculous therapy along with steroids | - | - | - | - | 1件: 84 84 |
| 2 | Cyclophosphamide and steroids | 1件: Cyclophosphamide Cyclophosphamide | 2件: D00287
D00287
,
D07760
| - | - | 1件: 222 222 |
| 3 | IV methylprednisolone (steroids) | 1件: Methylprednisolone Methylprednisolone | 1件: D00407
D00407
| 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 13 13 |
| 4 | Steroids | - | - | - | - | 7件: 46 46, 50, 51, 63, 66, 96, 97 |
| 5 | Steroids plus azathioprine | 1件: Azathioprine Azathioprine | 1件: D00238
D00238
| - | - | 1件: 66 66 |
| 6 | Symptomatic Treatment, Steroids, Immunosuppressive Agents, Plasma Exchange(PE), Intravenous Immunoglobulin(IVIg) | 1件: Human immunoglobulin G Human immunoglobulin G | - | - | - | 1件: 11 11 |
| 7 | Tocilizumab and IV steroids combination | 1件: Tocilizumab Tocilizumab | 1件: D02596
D02596
| 1件: IL6R IL6R 💬 | 12件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬 | 1件: 41 41 |